Program
Daunorubicin
Also written as “daunorubicin + cytarabine”, “daunorubicin hydrochloride” and “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”.
Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jazz Pharmaceuticals | 10 open or running | phase 1since Oct 16, 2006 | Oct 16, 2006 | none ahead |
| Kanisa Pharmaceuticals | 10 open or running | phase 2since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Kura Oncology | 11 open or running | phase 3since May 16, 2025 | May 16, 2025 | Nov 2031phase 3 · NCT07007312 |
| Novartis | 10 open or running | phase 1since Oct 6, 2004 | Oct 6, 2004 | none ahead |
| Pfizer | 10 open or running | phase 3since Dec 21, 2017 | Dec 21, 2017 | none ahead |
| Sichuan Biokin Pharmaceutical | 11 open or running | phase 3since Nov 20, 2025 | Nov 20, 2025 | Dec 2027phase 3 · NCT07255872 |
| Sumitomo Pharma | 10 open or running | phase 1since Sep 27, 2017 | Sep 27, 2017 | none ahead |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2004First study: phase 1 study in Leukemia, Myeloid, AcuteNew to NovartisNovartis · NCT00093600 · 69 enrolled · United States, Germany
- Aug 9, 2005Kanisa Pharmaceuticals's first study: phase 2 study in Leukemia, MyeloidNew to Kanisa PharmaceuticalsKanisa Pharmaceuticals · NCT00129168 · 100 enrolled
- Oct 16, 2006Jazz Pharmaceuticals's first study: phase 1 study in Hematologic NeoplasmsNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT00389428 · 48 enrolled · United States
- Sep 27, 2017Sumitomo Pharma's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
- Dec 21, 2017Pfizer's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
- May 16, 2025Kura Oncology's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
- Nov 20, 2025Sichuan Biokin Pharmaceutical's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
- Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor; DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Doxorubicinrule | Hoffmann-La Roche | phase 4 | 61 |
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| amrubicinrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07255872Leukemia, Myeloid, Acute · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2027 | 216 |
| NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Recruiting | Kura Oncology | Nov 2031 | 1,300 |
| NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Pfizer | Jun 5, 2020 | 730 |
| NCT03298984Leukemia, Myeloid, Acute · United States | 1 | Completed | Sumitomo Pharma | Mar 20, 2020 | 32 |
| NCT00389428Hematologic Neoplasms · United States | 1 | Completed | Jazz Pharmaceuticals | Dec 2008 | 48 |
| NCT00129168Leukemia, Myeloid | 2 | Completed | Kanisa Pharmaceuticals | Mar 2008 | 100 |
| NCT00093600Leukemia, Myeloid, Acute · United States, Germany | 1 | Completed | Novartis | Jun 2011 | 69 |
How it is read
Names in the registry
- “Daunorubicin”, 4 entries
- “daunorubicin + cytarabine”, 1 entry
- “daunorubicin hydrochloride”, 1 entry
- “CPX-351 (Cytarabine:Daunorubicin) Liposome Injection”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 6 studies
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.